A preliminary Phase 2 clinical trial has demonstrated that patients with acute ischemic stroke, the most common type of stroke, can safely tolerate high doses of 3K3A-APC, a promising anti-stroke drug.
from Top Health News – ScienceDaily http://bit.ly/2CxiizP
from Tumblr http://bit.ly/2C9lYfp
No comments:
Post a Comment